02715cam a2200337 a 4500 EG-GiCUC 20250223032525.0 200220s2020 ua dh f m 000 0 eng d EG-GiCUC eng EG-GiCUC eng Deposite Ph.D Cai01.08.08.Ph.D.2020.Om.F Omar Ali Abdalla Elkady Formulation and characterization of promising carrier systems for pulmonary drug delivery / Omar Ali Abdalla Elkady ; Supervised Hanan M. Ellaithy , Mina Ibrahim Tadros صياغة وتوصيف أنظمة حمل واعدة لتوصيل العقار رئويا Cairo : Omar Ali Abdalla Elkady , 2020 131 P. : charts , facsimiles ; 25cm Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Risedronate sodium (RS) is a potent inhibitor of bone resorption; having an extreme poor permeability and limited oral bioavailability (0.62%). RS should be orally administered under fasting conditions, while keeping in an upright posture for at least 30 min, to diminish common gastroesophageal injuries. To surmount such limitations, novel Risedronate-chitosan (RS-CS) crosslinker-free nebulizable microspheres were developed adopting quality by design (QbD) approach and Risk assessment (RA) thinking. RS:CS ratio, surfactant (Pluronic® F127) concentration, homogenization duration, speed and temperature were identified using Ishikawa diagrams as the highest formulation- and process-risk factors affecting the critical quality attributes (CQAs); average particle size (PS) and entrapment efficiency (EE%). The risk factors were screened using Plackett-Burman design and the levels of the most significant factors were optimized using a multi-level factorial-design to explore the optimized system with the least PS, maximum EE% and a prolonged drug release profile. The optimized system (B6) was developed at RS:CS ratio of 1:7, a surfactant concentration of 2% (w/v) and a homogenization speed of 14000 rpm. It revealed well correlation with QbD theoretical prediction where, positively charged (47.9±3.39 mV) discrete, spherical microspheres (3.47±0.16 æm), having a high EE% (94.58±0.19%) and prolonged RS release over 12 hours (Q12h, 89.70±0.64%) were achieved Issued also as CD Chitosan Crosslinker-free Risedronate sodium Hanan M. Ellaithy , Supervisor Mina Ibrahim Tadros , Supervisor http://172.23.153.220/th.pdf Asmaa Cataloger Nazla Revisor ddc TH 76716 76716 ddc 0 CUCL cl210 2024-02-11 Cai01.08.08.Ph.D.2020.Om.F 01010110080863000 2023-09-22 00:00:00 TH ddc 0 CUCL cl2u8 2024-02-11 Cai01.08.08.Ph.D.2020.Om.F 01020110080863000 2023-09-22 00:00:00 80863.CD CD